28 Oct 2014
Dexamethasone 3.8 mg/ml solution for injection (marketed by Aspen Pharma Trading Limited) is replacing Dexamethasone 4 mg/ml Injection (marketed by Organon Laboratories Limited) with changes to concentration, storage conditions and presentation.
From 1 October 2014, once all residual stock of Dexamethasone 4 mg/ml Injection is exhausted, all new orders will be supplied as Dexamethasone 3.8 mg/ml solution for injection.
The re-formulation has resulted in important changes to concentration, storage conditions and presentation. For a full description of the new product information, please visit the electronic medicines compendium (eMC) website.
Malcolm Donaldson 1949 - 2024
01 Oct 2024
Opportunity – Healthcare technology that works for young people focussing on transition
27 Sept 2024
Radioactive iodine therapy linked to evelated melanoma risk
27 Sept 2024
Breast cancer-causing chemicals discovered in food packaging
26 Sept 2024